Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7

The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC). However, in terms of safety, apatinib toxicities may lead to a dose modification or treatment interruption. Therefore, proper intervention is urgently needed to help...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Ma, Ling, Wang, Zhangding, Xie, Mengyan, Quan, Yunlin, Zhu, Weiyou, Yang, Fengming, Zhao, Chenhui, Fan, Yu, Fang, Na, Jiang, Huning, Wang, Qiang, Wang, Shouyu, Zhou, Jianwei, Chen, Xiaofeng, Shu, Yongqian
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058073/
https://ncbi.nlm.nih.gov/pubmed/32139670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2352-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados